Rheumatology News

WASHINGTON — Children with lupus from areas of lower socioeconomic opportunity experience more severe disease complications and poorer outcomes than those from higher opportunity areas, according to data presented at ACR Convergence 2024.

WASHINGTON — A focus on patient follow-up, standardized medication adherence and barriers assessments can reduce racial and ethnic disparities in juvenile idiopathic arthritis, according to a speaker at ACR Convergence 2024.

WASHINGTON — Patients with inflammatory arthritis who receive rituximab, interleukin-6 inhibition or Janus kinase inhibitors demonstrate higher severe infection risks vs. TNF inhibitors, according to data presented at ACR Convergence 2024.

WASHINGTON — Withholding Janus kinase or interleukin-17 inhibitors from patients with rheumatoid arthritis or spondyloarthritis does not significantly benefit COVID-19 booster response, according to data presented at ACR Convergence 2024.

Despite a lack of “gold standard” evidence surrounding cannabis use for musculoskeletal pain, rheumatologists must not turn a blind eye to how such products are used by their patients in the real world, according to researchers.

Hand and whole body MRI can objectively measure improvements in joint and enthesis inflammation resulting from apremilast treatment for psoriatic arthritis, according to data published in The Lancet Rheumatology.

Black and multiracial children with systemic lupus erythematosus demonstrate higher disease activity and are less likely to achieve low disease activity compared with white children, according to data published in Arthritis Care & Research.

Patients with severe Behçet’s syndrome who received infliximab demonstrated better odds of achieving complete response at 22 weeks compared with those who used cyclophosphamide, according to head-to-head data published in NEJM Evidence.

Deucravacitinib is superior to placebo for improving response across all domains of minimal disease activity criteria in patients with psoriatic arthritis at 16 weeks, according to data published in Rheumatology.